Georgia’s medical cannabis program is expanding even as state regulators wait for input from the DEA. Here’s why it matters and what DMV readers should watch.

Federal cannabis rescheduling is expected to pull producers under the same GMP standards that govern other consumed products, with new equipment rules likely to follow.

A new DEA registration pathway pulls state-licensed medical cannabis manufacturers, distributors, and labs into the federal Schedule III framework—potentially easing 280E tax pain.

High Times reports NORML’s Paul Armentano sees a two-front squeeze: GOP rollbacks in several states and Democratic tax hikes in others. Here’s what DMV consumers should watch.

DEA’s 2026 Drugs of Abuse update says no deaths from marijuana overdose and reflects federal moves toward Schedule III for certain cannabis products. Here’s what it means in practice.

New York’s legal cannabis market is tracking toward a new annual high while early indicators point to a cooling trend. Here’s what that mix of growth and hesitation could mean for delivery, compliance, and DMV operators watching from the sidelines.

arb420 is led by longtime cannabis attorneys Matt Goldberg and Andrew DeWeese. Here’s why specialized dispute resolution matters for delivery operators and brands.

A DEA administrative judge paused the cannabis rescheduling hearing to consider a GAO watchdog report on process gaps. A DEA response is due by October 13, adding delay and uncertainty.

Shannon O’Brien files a fresh lawsuit alleging misconduct and public safety risks in a $1.6B market. Here’s why DMV delivery operators should care about the fallout.

Curaleaf launched a hostile takeover offer for Aurora, moving the proposal directly to investors. Here’s what that could mean for product supply, delivery compliance, and DMV consumers.

As microdosing goes mainstream, here’s how to decide between a solo approach or working with a coach—plus DMV-specific considerations and compliance tips.

California approved two cannabis bills focused on product testing, tracking, consumer information and cannabinoid content. Here’s what changed, how it may ripple beyond CA, and what DMV readers should watch next.

Through July 11, Ohio’s medical and adult-use cannabis market tallied $684.6 million and 150.3 million units sold, a pace MJBizDaily says could set a new annual high.

Pennsylvania’s House speaker says legalization is within reach next year if the state Senate shifts—raising big questions about delivery rules, licensing and compliance.

MJBizDaily reports Tilray is boosting medical cannabis capacity with cultivation in Quebec and Portugal. Here’s how Canadian LPs’ European push intersects with DMV delivery rules.

MiCIA backs John James for pledging to repeal a new 24% wholesale tax. A Democratic senator warns his record on legalization and Congress undercuts the promise.

Why a 40 Under 40 honoree’s focus on discovery and smarter deal-finding matters for cannabis delivery laws, compliance, and shoppers across the DMV.

Marijuana Venture’s 40 Under 40 nod for Rocco Del Priore spotlights a tech arms race. Here’s how bigger dev teams can shape cannabis delivery compliance in the DMV.

California’s Q2 cannabis retail sales reached $1.013B and held steady year over year, hinting at stabilization and new lessons for delivery teams.

A unanimous Nebraska Supreme Court rejected a bid to void the state’s voter-approved medical cannabis laws on standing grounds, leaving the program in place—for now.